Taken together, these findings outline a liver‐peripheral crosstalk mediated by SREBP2‐ANGPTL3‐LPL axis and suggest that SREBP2 inhibition can be an effective strategy to tackle homozygous familial hypercholesterolemia (HoFH). The gene discussed is SREBF2; the disease is homozygous familial hypercholesterolemia.